Journal of tropical medicine · 2026
Association of Helicobacter pylori Coinfection With Tuberculosis Disease Severity and Treatment Outcomes.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Baluku Joseph Baruch, Ichumar Mary Magdalen, Zawedde Daphine, Nabwana Martin, Nanyanzi Diana, Wanda Harriet Yvonne, Namiiro Sharon, Namanda Brenda, Nabawanuka Eva, Kikomeko Sharif, Mutesi Judith, Kansiime Grace, Nuwagira Edwin, Kraef Christian, Rhein Joshua, Seremba Emmanuel, Munabi Ian G, Kiguli Sarah
Аннотация
BACKGROUND: Helicobacter pylori (HP) has immunomodulatory properties, but its relationship with tuberculosis (TB) severity and outcomes remains uncertain. We evaluated the association between HP infection and TB severity and explored factors associated with HP coinfection and TB treatment outcomes.
METHODS: We enrolled adults (≥ 18 years) with drug-sensitive, newly diagnosed, bacteriologically confirmed pulmonary TB from two public clinics in Uganda. HP infection was determined using stool antigen testing. Severe TB was defined as GeneXpert cycle threshold < 16 or smear grade 3+ (microbiological), Bandim TBscore ≥ 8 (clinical), and chest X-ray Timika score > 71 (radiological). Treatment outcomes were determined ≥ 7 months after treatment initiation.
RESULTS: Among 200 participants, 67 (33.5%) were HP positive. Severe radiological TB was more frequent among HP-positive participants (34.8% vs. 22.1%, p = 0.060). Severe clinical (14.9% vs. 11.3%, p = 0.549) and microbiological TB (40.0% vs. 33.8%, p = 0.856) were also more frequent in HP. HP was not significantly associated with severe radiological (adjusted prevalence ratio [aPR] 1.56; 95% CI 0.96-2.53, p = 0.074), clinical (aPR 1.17; 95% CI 0.53-2.60, p = 0.694), or microbiological TB (aPR 1.14; 95% CI 0.80-1.63, p = 0.462). HP coinfection was independently associated with rural residence (aPR 1.61; 95% CI 1.04-2.47, p = 0.031), anorexia (aPR 1.72; 95% CI 1.01-2.90, p = 0.045), and lower diastolic blood pressure (aPR 0.98; 95% CI 0.96-1.00, p = 0.013). TB treatment success was similar among those with and without HP (95.5% vs. 95.5%, p = 0.180).
CONCLUSION: HP was not significantly associated with TB severity or outcomes, though a trend toward greater radiological severity warrants further investigation in larger, prospective studies.
METHODS: We enrolled adults (≥ 18 years) with drug-sensitive, newly diagnosed, bacteriologically confirmed pulmonary TB from two public clinics in Uganda. HP infection was determined using stool antigen testing. Severe TB was defined as GeneXpert cycle threshold < 16 or smear grade 3+ (microbiological), Bandim TBscore ≥ 8 (clinical), and chest X-ray Timika score > 71 (radiological). Treatment outcomes were determined ≥ 7 months after treatment initiation.
RESULTS: Among 200 participants, 67 (33.5%) were HP positive. Severe radiological TB was more frequent among HP-positive participants (34.8% vs. 22.1%, p = 0.060). Severe clinical (14.9% vs. 11.3%, p = 0.549) and microbiological TB (40.0% vs. 33.8%, p = 0.856) were also more frequent in HP. HP was not significantly associated with severe radiological (adjusted prevalence ratio [aPR] 1.56; 95% CI 0.96-2.53, p = 0.074), clinical (aPR 1.17; 95% CI 0.53-2.60, p = 0.694), or microbiological TB (aPR 1.14; 95% CI 0.80-1.63, p = 0.462). HP coinfection was independently associated with rural residence (aPR 1.61; 95% CI 1.04-2.47, p = 0.031), anorexia (aPR 1.72; 95% CI 1.01-2.90, p = 0.045), and lower diastolic blood pressure (aPR 0.98; 95% CI 0.96-1.00, p = 0.013). TB treatment success was similar among those with and without HP (95.5% vs. 95.5%, p = 0.180).
CONCLUSION: HP was not significantly associated with TB severity or outcomes, though a trend toward greater radiological severity warrants further investigation in larger, prospective studies.